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N-Terminal Pro–B-Type Natriuretic Peptide–Guided,
Intensive Patient Management in Addition to
Multidisciplinary Care in Chronic Heart Failure
A 3-Arm, Prospective, Randomized Pilot Study
Rudolf Berger, MD,* Deddo Moertl, MD,* Sieglinde Peter, RN,* Roozbeh Ahmadi, MD,*
Martin Huelsmann, MD,* Susan Yamuti, RN,† Brunhilde Wagner, MD,‡ Richard Pacher, MD*
Vienna, Austria
Objectives This study was designed to investigate whether the addition of N-terminal pro–B-type natriuretic peptide–guided,
intensive patient management (BM) to multidisciplinary care (MC) improves outcome in patients following hospi-
talization due to heart failure (HF).
Background Patients hospitalized due to HF experience frequent rehospitalizations and high mortality.
Methods Patients hospitalized due to HF were randomized to BM, MC, or usual care (UC). Multidisciplinary care included 2
consultations from an HF specialist who provided therapeutic recommendations and home care by a specialized
HF nurse. In addition, BM included intensified up-titration of medication by HF specialists in high-risk patients.
NT-proBNP was used to define the level of risk and to monitor wall stress. This monitoring allowed for anticipa-
tion of cardiac decompensation and adjustment of medication in advance.
Results A total of 278 patients were randomized in 8 Viennese hospitals. After 12 months, the BM group had the highest pro-
portion of antineurohormonal triple-therapy (difference among all groups). Accordingly, BM reduced days of HF hospi-
talization (488 days) compared with the hospitalization for the MC (1,254 days) and UC (1,588 days) groups (p 
0.0001; significant differences among all groups). Using Kaplan-Meier analysis, the first HF rehospitalization (28%)
was lower in the BM versus MC groups (40%; p  0.06) and the MC versus UC groups (61%; p  0.01). Moreover, the
combined end point of death or HF rehospitalization was lower in the BM (37%) than in the MC group (50%; p 
0.05) and in the MC than in the UC group (65%; p  0.04). Death rate was similar between the BM (22%) and MC
groups (22%), but was lower compared with the UC group (39%; vs. BM: p  0.02; vs. MC: p  0.02).
Conclusions Compared with MC alone, additional BM improves clinical outcome in patients after HF hospitalization. (BNP
Guided Care in Addition to Multidisciplinary Care; NCT00355017) (J Am Coll Cardiol 2010;55:645–53)
© 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.078c
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mespite advances in therapy, about 30% of chronic heart
ailure (CHF) patients are readmitted within 60 to 90 days
ollowing heart failure (HF) hospitalization, and about 10%
f them are dying within this time span (1). These poor
ischarge outcomes can be attributed to suboptimal care
ssociated with the patients’ lack of understanding of their
ondition, poor treatment compliance, as well as inadequate
edical prescription and follow-up (2). For optimizing
utpatient care, the involvement of specialized HF nurse
rom the Departments of Cardiology of the *Medical University of Vienna, †Hospital
f Hietzing, and ‡Hospital Sozialmedizinisches Zentrum Ost, Vienna, Austria. This
tudy was funded by AstraZeneca, Novartis, Roche Diagnostics, Roche Medical,
erck, Medtronic, and Guidant, who provided the financial support for a clinical
nvestigator, a specialized chronic heart failure nurse, and data collection.i
Manuscript received November 13, 2008; revised manuscript received July 6, 2009,
ccepted August 31, 2009.are and the increased accessibility to clinicians trained in
F are crucial in reducing rehospitalization rate and mor-
ality (3). Despite variations in the role of HF nurses in
ifferent health care settings, the basic principles are similar.
he nurses are usually responsible for history taking, clinical
ssessment, and patient management, which includes ad-
ustment and titration of medication (4); the associated HF
linicians provide titration plans and get involved in the
anagement of patients with clinical deterioration and
ardiac decompensation.
Disease management programs focus on patients discharged
fter HF hospitalization, as these patients are at higher risk for
eadmission. Despite severe cardiac dysfunction, these patients
eport few or no symptoms after recompensation. This finding
ay result from patients’ perception that symptoms havemproved or from the fact that patients do not return to their
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talization or immediately after dis-
charge (5). In contrast to symp-
toms, B-type natriuretic peptide
(BNP) is an objective prognostic
marker that better predicts survival
than traditional prognostic indi-
cators in HF (6). Patients with
high risk for early rehospitaliza-
tion and death can be effectively
identified by assessing levels of
natriuretic peptides (NPs) at dis-
charge, as recently shown (7,8).
This prognostic capacity of NPs
might improve the management
of discharged patients by identi-
fying those requiring more inten-
sive outpatient care.
Moreover, NPs may also be
useful in objectively detecting
hort-term improvement or deterioration. A recent study
emonstrated that in high-risk patients, as identified by
igh N-terminal pro–B-type natriuretic peptide (NT-
roBNP), short-term changes of NT-proBNP add signifi-
ant prognostic information to its absolute value (9). These
hanges of NT-proBNP correlate with hemodynamic alter-
tions (10) and seem to be a reliable diagnostic tool for
onitoring changes in fluid status and/or cardiac function.
NT-proBNP measurement offers 2 diagnostic opportunities
or the management of HF patients: 1) global risk assessment,
hich allows the intensive patient treatment by HF specialists
o be focused on patients with the highest risk for decompen-
ation; and 2) monitoring of short-term changes in wall stress,
hich allows for anticipation of cardiac decompensation and
djustment of medication in advance. We used these 2 diag-
ostic opportunities for NT-proBNP–guided, intensive man-
gement (BM) of patients discharged after HF hospitalization.
herefore, we investigated whether the benefit of multidisci-
linary care (MC) compared with usual care (UC) can be
ncreased by adding BM.
ethods
he study was conducted in 8 Viennese hospitals and
ncluded patients who met the following criteria: 1) clinical
igns and symptoms of cardiac decompensation during the
resent hospitalization; 2) New York Heart Association
unctional class III or IV at admission; and 3) cardiothoracic
atio 0.5 or left ventricular ejection fraction 40% as
ocumented by echocardiography. This 3-arm pilot study
as approved by relevant ethical committees for each
articipating hospital. Written informed consent was ob-
ained from all patients.
At discharge, concealed allocation was performed by
ending the baseline characteristics of each patient to an
ndependent medical project management institute (RESULT
Abbreviations
and Acronyms
ACE-I  angiotensin-
converting enzyme inhibitor
BM  N-terminal pro–B-
type natriuretic peptide-
guided, intensive patient
management
BNP  B-type natriuretic
peptide
CHF  chronic heart failure
HF  heart failure
MC  multidisciplinary
care
NP  natriuretic peptide
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
UC  usual careRO Data GmbH, Vienna, Austria). Using computer- cenerated permuted block randomization (6 patients per
lock), patients were randomized to the 3 groups: 1) BM in
ddition to MC; 2) MC alone; and 3) UC. Patients were
onitored for a maximum period of 18 months. Follow-up
as closed when the last patient included in the study
ompleted the 12-month visit.
C. For patients assigned to UC, their management plan
as sent to the appropriate primary care physician, who was
sked to implement it. Based on this management plan, the
rimary care physician was responsible for the patient
valuation and treatment as well as judging the need for
eadmission. In hospitals in which the usual patient man-
gement offered visits for selected patients at the cardiac
utpatient clinic, the discharging physician was allowed to
rrange such visits as usual. Contact with the HF specialists
f the research team was discouraged. Neither a structured
ollow-up nor specialized HF nurses were available for
atients in the UC group. A phlebotomist collected blood
amples and tracked medical therapy 1, 3, 6, and 12 months
fter discharge for scientific reasons. In case of questions
oncerning HF management, patients were asked to contact
heir primary care physician.
C. MC comprised care by a specialized CHF nurse, which
ncluded 4 home visits and telephone contact, 2 pre-scheduled
onsultations from the CHF specialist 10 days and 2 months
fter discharge, and consultations on demand that were per-
ormed if any deterioration in the patient’s status was noted by
he HF nurse. During the first consultation, the full clinical
istory was evaluated. Each consultation consisted of a physical
xamination (including measurement of blood pressure and
ody weight) where functional status and HF medication were
ocumented and a 12-lead electrocardiogram was reviewed.
oreover, laboratory testing including blood chemistry and
lood cell count was performed. Based on these data, a tailored
ecommendation for the optimization of medical therapy was
rovided. This included a preparation of an individual titration
lan, adjustment of diuretics, and recommendations for dis-
ontinuation of inappropriate medication. Furthermore, the
F specialist scheduled laboratory tests checking electrolytes
nd renal parameters at least 1 week after each dose adaptation
r addition of medication and 3 months after optimization of
edical therapy.
Nurse care consisted of 4 home visits at 1, 3, 6, and 12
onths after discharge by a nurse specialized in caring for
HF patients. The nurse checked and recorded weight,
ymptoms and signs of HF, and heart rate and blood
ressure, as well as organized and reviewed blood analyses
n demand (particularly electrolytes and renal parameters).
n coordination with the HF specialist, the nurse checked
or and implemented guideline-based HF medication. Ad-
itionally, the nurse was in charge of individualized patient
nd caregiver education and enhancement of self-
anagement. When necessary (as judged by the nurse),
dditional visits were performed. If any deterioration in the
atient’s status was noted, the nurse either reported to the
F specialist or immediately advised the patient to seekonsultation.
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February 16, 2010:645–53 NT-ProBNP–Guided, Intensive Patient ManagementM. In patients with a discharge NT-proBNP level 2,200
g/ml, ambulatory visits at a CHF specialist were performed at
east every 2 weeks (except at scheduled nurse visits) in addition
o MC to optimize medical therapy as quickly as possible.
hen NT-proBNP fell below 2,200 pg/ml 3 or 6 months
fter discharge, patients were followed similarly to those in the
C group. In patients with an ongoing elevated NT-proBNP
2,200 pg/ml, the every-2-weeks visits were continued until
aximal recommended or tolerated dosages of CHF therapy
ere established, following which the time interval between
isits was increased to 3 months. The HF specialist used
T-proBNP in addition to other clinical and laboratory
arameters for integrated clinical management (e.g., adaptation
f diuretic regimen, rate of dose increase for neurohormonal
ntagonists, schedule of visits) according to the recommenda-
ions given in Figure 1.
T-proBNP levels. Blood samples for measurement of
T-proBNP (Roche Diagnostics, Mannheim, Germany)
ere drawn at 1, 3, 6, and 12 months following discharge in
ll available patients. The NT-proBNP levels were analyzed
mmediately in all patient samples; however, only the results
rom the BM group were delivered immediately to the HF
pecialists, whereas the results from the other 2 groups were
ot made available for clinical use.
In 2 studies, the pre-discharge BNP cutoff values were
alculated to be 350 pg/ml and 430 pg/ml for prediction of
F rehospitalization and death, respectively (7,8). How-
ver, no data are available for NT-proBNP. We converted
he lower BNP value of 350 pg/ml to an NT-proBNP value.
conversion factor of 9 was used, which resulted from an
nalysis of our own data on simultaneous determination of
NP and NT-proBNP in CHF patients (D. Moertl and R.
erger, unpublished data, October 2002). This factor was
lso confirmed by Richards et al. (11). Due to the known
ntraindividual variability of 30% (12), we used a safety
argin adjusted to the known intraindividual variability of
0% (12). Overall, the cutoff value for NT-proBNP of 2,200
g/ml was based on a converted BNP cutoff of 350 pg/ml
nd a safety margin of 30%.
utcome data. The analyzed end points included HF
ehospitalization, duration of time it takes to reach the
ombined end point of death and HF rehospitalization, the
rst HF rehospitalization, and death. Independent data
ollectors obtained information from medical reports and
rom interviews with relatives during the follow-up at least
very 3 months. During a consensus reading, 2 cardiologists,
ho were blinded to the treatment groups, classified the
ause of rehospitalization as being a result of cardiac
ecompensation or not. If the cause of rehospitalization was
lassified unclear by 1 cardiologist, the data collector pro-
ided the appropriate hospital charts for final classification.
tatistical analysis. Data analyses were performed according
o the intention-to-treat principle. Continuous variables are
xpressed as mean SD. Continuous variables were compared
sing a 1-factor analysis of variance followed by Fisher t test.
rdinal data were compared using a Kruskal-Wallis testollowed by Shaffer-corrected U tests. Categorical data were pompared using a chi-square test. For calculations, NT-
roBNP values were log-transformed due to the nonparamet-
ic distribution. A paired t test was performed to estimate
hanges in the log-transformed NT-proBNP values between
ischarge and follow-up. Mean, median, lower and upper
uartiles, and 95% confidence intervals (box plot) were com-
uted on the log-scale and back-transformed to the original
cale. Follow-up data were defined as those collected from the
2-month visit or the last available visit. Kaplan-Meier analy-
es with log-rank test were calculated for comparison of
ime-dependent outcomes. Cox proportional hazards models
ere used to determine independent predictors of the first HF
ehospitalization, death, and the combined end point of HF
ehospitalization and death. The full models included patient
haracteristics given in Table 1 and treatment allocation. The
odels were carried out using a stepwise approach. Each
ariable was required to meet the criterion p value of 0.05 in
rder to enter and remain in the model. Simple models that
ncluded treatment allocation, age, and an interaction term
treatment allocation  age) tested whether the effect of
reatment strategy was influenced by age.
esults
atients. Between July 2003 and September 2004, 278 of 441
ligible patients were randomized (Fig. 2). Patients who
articipated were on average 5 years younger than nonpar-
icipants were. The study ended in September 2005, after a
-year follow-up of the last patient included in the study.
ixty-three percent of patients completed the 18-month
bservation period, whereas the remaining 37% were fol-
owed for a median of 15 months (interquartile range 13 to
6 months). Their characteristics are given in Table 1; no
ifferences could be detected among groups.
mbulatory visits and telephone contacts. The total
umber of consultations of the HF specialist was similar in
he BM (n 564) and MC (n 511) groups. This was due
o the fact that in the BM group repeated scheduled visits
ere performed only in high-risk but not in low-risk
atients. At the same time, the number of unscheduled
isits was slightly higher in the MC group. In contrast, the
otal number of visits was significantly lower in the UC
roup (n  229; p  0.0001 among groups) (Table 2).
edical therapy. Table 3 lists medical therapy at discharge
nd at follow-up. The proportion of patients treated with
ntineurohormonal triple therapy including spironolactone
nd 50% of the target doses of an angiotensin-converting
nzyme inhibitor (ACE-I)/angiotensin receptor blocker and
f a beta-blocker was higher in the BM group than in the
C group (Fig. 3). During outpatient care, the furosemide
ose was adjusted more frequently in the BM group (sum of
ose changes  273) than in the MC group (n  231) and
he UC (n  150) groups (p  0.0001; significant differ-
nces among all groups).
T-proBNP levels. The proportion of patients with an
T-proBNP level above 2,200 pg/ml was similar amongatients in the BM (53%), MC (56%), and UC (56%)
g
t
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o follow-up was more pronounced in the BM group than in
he MC group. No decrease was observed in the UC group
Figure 1 Recommendations for BM
N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels were used to determin
(NT-proBNP 2,200 pg/ml) for intensified care by heart failure (HF) specialists an
after 3 or 6 months. In high-risk patients, the course of NT-proBNP levels was use
ment (e.g., adaptation of diuretic regimen, speed of dose-increase of neurohormon
tor (ACE-I)/angiotensin receptor blocker (ARB) or beta-blocker only in the absence
mg/dl or 50% of serum creatinine 2.5 mg/dl); and 3) for beta-blocker, heart ra
patient management; BP  blood pressure; iv  intravenous; MC  multidisciplin
system.Fig. 4). sutcome. BM reduced days of HF hospitalization (488
ays) when compared with hospitalization for the MC
1,254 days) and UC groups (1,588 days) (p  0.0001;
intensity of care during medical optimization, thereby selecting high-risk patients
arging them from this care in case of a decrease of NT-proBNP 2,200 pg/ml
dition to other clinical and laboratory parameters for integrated clinical manage-
agonists, schedule of visits). *Increase of angiotensin-converting enzyme inhibi-
symptomatic hypotension; 2) significant increase of serum creatinine (0.3
0 beats/min. BM  N-terminal pro–B-type natriuretic peptide-guided, intensive
e; NYHA  New York Heart Association; RAAS  renin-angiotensin-aldosteronee the
d disch
d in ad
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of: 1)
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ary carignificant differences among all groups). Using Kaplan-
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ower in the BM group than in the MC group (40%; p 
.06), and in the MC versus UC group (61%; p  0.01).
oreover, the combined end point of death or HF
ehospitalization (Fig. 5) was lower in the BM (37%)
Assessed for el
278 patients 
Usual Care Multidisc
Allocated to intervention
(n=90)
Received allocated intervention
(n=90)
No patient was lost to follow-
up, no patient discontinued 
i t ti
Allocated to in
(
Received alloc
(
No patient was
up, no patient 
i t tin erven on
Analyzed  (n=90)
n erven on
Analyzed  (n=
Figure 2 Consort Diagram
A total of 462 patients were screened for the study, of which 21 patients never m
163 refused to participate, and the remaining 278 patients were randomized to B
Patient CharacteristicsTable 1 Patient Characteristics
Variable
UC
(n  90)
Mean age, yrs 71 13
Women 31
Primary cause of heart failure
Coronary artery disease 68
Hypertension 21
Valve-related 2
Other 9
Comorbidities
Previous myocardial infarction 46
Hypertension 67
Atrial fibrillation 31
Stroke 14
Chronic obstructive lung disease 21
Diabetes 33
Left ventricular systolic function
Preserved 8
Mild to moderately reduced 31
Severely reduced 61
NT-proBNP, pg/ml* 2,359 (355–15
Systolic blood pressure, mm Hg 123 21
Diastolic blood pressure, mm Hg 71 14
Heart rate, beats/min 77 16
Serum creatinine 2 mg/dl 17
Values are mean SD or % unless otherwise indicated. *Mean and 95%
to the original scale.
BM  N-terminal pro–B-type natriuretic peptide-guided, intensive p
pro–B-type natriuretic peptide; UC  usual care.han in the MC group (50%; p  0.05), and in the MC
ersus UC group (65%; p  0.04). Death rate was similar
etween the BM (22%) and MC groups (22%), but was
ower than the UC group (39%; vs. BM: p  0.02; vs.
C: p  0.02).
y (n=462)
Excluded  (n=184)
Not meeting inclusion criteria
(n=21)
Refused to participate
(n=163)ized
 Care NT-BNP Guided Patient 
Management 
ion
tervention
 follow-
inued 
Allocated to intervention
(n=92)
Received allocated intervention
(n=92)
No patient was lost to follow-up, 
no patient discontinued 
i t tin erven on
Analyzed  (n=90)
ibility criteria. Of 441 eligible patients,
92), MC (n  96), and usual care (n  90). Abbreviations as in Figure 1.
Nurse-Led MC
(n  96)
BM
(n  92)
73 11 70 12
30 37
64 61
25 23
5 2
6 14
49 42
69 65
33 30
10 12
17 15
47 45
9 2
18 20
73 76
2,469 (355–18,487) 2,216 (355–9,649)
122 18 119 19
72 12 72 13
80 17 79 19
17 15
ence intervals were computed on the log-scale and back-transformed
anagement; MC  multidisciplinary care; NT-proBNP  N-terminalig
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NT-ProBNP–Guided, Intensive Patient Management February 16, 2010:645–53In the multivariable model, NT-proBNP was the stron-
est independent predictor, with treatment allocation pro-
iding additional prognostic information for first HF rehos-
italization, death, and the combination of these end points.
eft ventricular systolic function and diabetes were other
ndependent predictors of first HF rehospitalization,
hereas chronic obstructive lung disease independently
redicted death. Treatment allocation and age were univar-
ate predictors of each end point. Using a simple model
ncluding age, treatment allocation, and an interaction term
etween these 2, we found no interaction between age and
reatment allocation indicating that treatment allocation
redicted outcome irrespective of age.
iscussion
his is the first study utilizing the prognostic power of
ischarge NPs for individualized post-discharge manage-
ent. Patients with high discharge NT-proBNP were
eferred to multidisciplinary management with intensified
are by a CHF specialist and transferred to a nurse-led
ultidisciplinary management as soon as NT-proBNP fell
elow the limit. This approach ensured rapid up-titration of
herapy guided by NT-proBNP in patients at highest risk
or cardiac decompensation. Consequently, such treatment,
hen compared with nurse-led multidisciplinary manage-
ent alone, was associated with a higher proportion of
ntineurohormonal triple therapy, more frequent adjust-
ents of diuretics, a more pronounced decrease in NT-
roBNP levels, and an improved outcome. The intensified
atient management, as used in the high NT-proBNP
ubgroup in BM, was not accompanied by an increase in
otal visits to the HF specialist. This was because of the shift
f intensified treatment from decompensated patients in
C to patients with imminent decompensation in BM,
nterventions and Days in Hospital Due to HFTable 2 Interventions and Days in Hospital Due to HF
Variable
UC
(n  90)
Nurse-Led MC
(n  96)
BM
(n  92)
Ambulatory visits at the CHF specialist
All visits* 229 511† 564†
Scheduled visits 220 336‡
In patients with NT-proBNP
2,200 pg/ml
116 215‡
In patients with NT-proBNP
2,200 pg/ml
104 121
Unscheduled visits 229 291 228
Telephone contacts with the CHF
specialist
103 263‡
Days in hospital due to HF* 1,588 1,254† 488†‡
Significant difference among groups (for all visits and for days in hospital due to heart failure [HF]:
 0.0001). †Significant difference compared with UC (for all visits: MC vs. UC and BM vs. UC, p
0.001; for days in hospital due to UC: MC vs. UC, p  0.04; BM vs. UC, p  0.001). ‡Significant
ifference compared with MC (for scheduled visits: p 0.0005; for scheduled visits in patients with
T-proBNP2,200 pg/ml: p 0.0002; for telephone contacts with the chronic heart failure [CHF]
pecialist: p  0.0001; for days in hospital due to HF: p  0.04).
Abbreviations as in Table 1.hich obviously served as a preventive strategy. aT-proBNP for treatment monitoring. Ambulatory
edical HF treatment includes antineurohormonal (and
asodilator) treatment as well as diuretic therapy. Both
reatment principles reduce ventricular wall stress, either by
educing pre-load and afterload and stopping and even
eversing ventricular remodeling, or by achieving and main-
aining euvolemia. Natriuretic peptides allow for direct
ssessment of this ventricular wall stress. Up to now, various
tudies used NPs as guidance for HF therapy, thereby
iming to decrease NP levels below a certain cutoff value:
NP 50 pg/ml (13), BNP 200 pmol/ml (14), BNP 100
g/ml (15), or NT-proBNP 2 times or less the upper limit
f normal (16,17). One study titrated ACE-Is up to doses
xceeding target doses and further added angiotensin-
eceptor blockers if necessary (13). Other studies intensified
rug treatment according to a stepwise protocol. One
rotocol started with maximization of ACE-Is, followed by
n increase in loop diuretic, then addition of digoxin,
nother diuretic, and finally addition of vasodilators (first
sosorbide mononitrate, then felodipine) (14). The protocol
f the TIME-CHF (Trial of Intensified versus Standard
edical Therapy in Elderly Patients with Congestive Heart
edical Therapy: Discharge and Follow-UpTable 3 Medical Therapy: Discharge and Follow-Up
Variable
UC
(n  90)
Nurse-Led MC
(n  96)
BM
(n  92)
Discharge
ACE-Is or ARBs 89 88 91
% of target dose 52 38 50 39 51 37
Beta-blockers 73 76 82
% of target dose 35 32 32 32 36 23
Spironolactone 37 42 45
Dose, mg/day 63 43 55 32 52 31
Triple therapy 7 4 7
Combination of
ACE-I and
ARB
0 0 0
Furosemide 81 78 85
Dose, mg/day 65 40 74 44 66 50
Follow-up
ACE-Is or ARBs 87 88 92
% of target
dose*
54 38 97 62† 100 64†
Beta-blockers 76 92 88
% of target
dose*
38 27 58 35† 73 39†‡
Spironolactone 46 49 53
Dose, mg/day 48 35 36 19 42 20
Triple therapy 9 20† 37†‡
Combination of
ACE-I and
ARB*
0 39† 44†
Furosemide 79 72 76
Dose, mg/day* 76 90 62 68 47 45†
alues are % or mean  SD. Triple therapy is spironolactone and 50% of the target dose of an
CE-I/ARB and of a beta-blocker. *Significant difference among groups (% of ACE-I or ARB target
ose: p  0.0001; % of beta-blocker target dose: p  0.0001; furosemide dose: p  0.05).
Significant difference compared with UC (for triple therapy: MC vs. UC, p  0.03; BM vs. UC, p 
.0001; for the combination of ACE-I and ARB: MC vs. UC, p  0.0001; BM vs. UC, p  0.0001).
Significant difference compared with MC (for triple therapy: BM vs. UC, p  0.009).
ACE-I  angiotensin-converting enzyme inhibitor; ARB  angiotensin-receptor blocker; other
bbreviations as in Table 1.
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February 16, 2010:645–53 NT-ProBNP–Guided, Intensive Patient Managementailure) (16) started with adding spironolactone and con-
inued with up-titration of ACE-Is, angiotensin-receptor
lockers, and beta-blockers; addition of loop diuretics;
ow-dose digoxin; long-acting nitrates; metolazone or
nother thiazide; molsidomide during nitrate-free intervals;
nd intravenous diuretics or inotropes. In the STARS-BNP
Systolic Heart Failure Treatment Supported by BNP)
tudy, medical treatment was intensified according to the
udgment of the investigator, an approach that resulted in a
hange of furosemide in 55% versus 26% of the patients,
pironolactone in 17% versus 7%, ACE-Is or angiotensin-
eceptor blockers in 21% versus 9%, and beta-blockers in
6% versus 20% of the patients (15). In these various
tudies, the NP-guided strategies were compared either
ith up-titration of neurohormonal therapy to target doses
Figure 3 Effect of UC, MC, and BM on Heart Failure Therapy
The proportion of triple therapy (spironolactone and 50% of the target dose
of an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and
of a beta-blocker) was similar among groups at baseline, but was higher in the
BM group versus the MC group, and higher in the MC versus the usual care
(UC) group at follow-up. Abbreviations as in Figure 1.
Figure 4 Baseline and Follow-Up Values of NT-ProBNP
Box plot with mean [], median, lower and upper quartiles, and 95% confidence in
follow-up was more pronounced in the BM group than in the MC group. No decreandependent of symptoms or with symptom-guided up-
itration of neurohormonal therapy as well as adjustment of
iuretics targeting clinical stability. The key objective of the
TARBRITE (Strategies for Tailoring Advanced Heart
ailure Regimens in the Outpatient Setting: Brain Natri-
retic Peptide versus the Clinical Congestion Score) study
17) was to test 2 different outpatient fluid-management
trategies, 1 strategy guided by BNP levels as well as clinical
argets and another strategy using clinical targets alone.
Regarding symptom- or NP-guided up-titration of neuro-
ormonal antagonists, 1 major criticism was that neurohor-
onal antagonists should be up-titrated to target doses proven
o prolong life or to maximally tolerated doses in all CHF
atients, irrespective of symptoms or NP levels (18), especially
s their effects on outcome are dose-dependent (19). In some
s: the decrease of NT-proBNP levels from discharge to
observed in the UC group. Abbreviations as in Figures 1 and 3.
Figure 5 Survival Without HF Hospitalization
Up to 18 months, the combined end point of death or heart failure (HF) hospi-
talization was lower in the BM (37%) versus MC group (50%; p  0.05) and in
the MC versus UC group (65%; p  0.04). Abbreviations as in Figures 1 and 3.terval
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ional (i.e., non–NP-guided) therapy tended to be under-
reated. In contrast, our study assessed NT-proBNP primarily
s guidance of patient management instead of medical therapy
y selecting high-risk patients for intensified management.
his concept of NP-guided management has now been taken
ver by a Danish group of investigators, who are testing the
ffects of close monitoring of high-risk patients (defined by
P) despite clinical stability under optimized medical therapy
20). In addition to the guidance of patient management, our
F specialists used NT-proBNP together with other clinical
nd laboratory parameters for integrated clinical management
e.g., adaptation of diuretic regimen, rate of dose-increase of
eurohormonal antagonists, or schedule of visits) in patients
ith levels2,200 pg/ml. According to the recommendations
resented in Figure 1, they reacted to increasing NT-proBNP
evels by intensifying the diuretic regimen (depending on renal
unction) and by interrupting or slowing further up-titration of
eta-blockers. In case of stable or decreasing NT-proBNP
evels, they fastened the up-titration of beta-blockers and
educed doses of diuretics. Patients whose NT-proBNP level
ecreased to 2,200 pg/ml within 3 or 6 months were
ischarged from intensified up-titration management by CHF
pecialists but still received ongoing care by the nurse-led
ultidisciplinary approach. With this management design,
ptimization of CHF therapy was achieved in all patients
ithin months, but intensified care by CHF specialists was
eserved only for patients at highest risk of cardiac decompen-
ation as estimated by high NT-proBNP levels. Thereby, BM
mproved the outcome of CHF patients, even when compared
ith nurse-led MC alone, which is currently regarded as
ptimal care for ambulatory CHF patients.
We decided not to change the treatment strategy in
esponse to NT-proBNP until 3 months had elapsed, which
e believed was necessary for medical up-titration in high-
isk patients. Moreover, a significant decrease of NT-
roBNP could not be expected before 3 months, as treat-
ent with renin-angiotensin-aldosterone system antagonists as
ell as beta-blockers had to be optimized in most patients.
uring alternate up-titration, the decrease of natriuretic
eptides by renin-angiotensin-aldosterone system antago-
ists is counterbalanced by the opposing effect of beta-
lockers on plasma NPs (21).
ole of CHF specialists in multidisciplinary management.
edical up-titration in severe CHF patients with the highest
isk is the most challenging. A subgroup analysis from the
OPERNICUS (Effect of Carvedilol on Survival in Severe
hronic Heart Failure) trial revealed that the most severe
atients at the highest risk had the highest rate of carvedilol
ithdrawal (20%) and failure of reaching target doses (50%).
owever, they also had the highest absolute benefit from
arvedilol (22). It is difficult to up-titrate beta-blockers in these
atients, as side effects such as hypotension and associated renal
ysfunction or decompensation are likely to occur. Similarly,
he up-titration of renin-angiotensin-aldosterone system an-
agonists and their combined use can cause acute renal failure
nd hyperkalemia (23). The important role of specialist care in pevere CHF patients at the highest risk has been recently
uggested (24). Therefore, in these patients the potential for
edical up-titration in usual and ambulatory nurse care must
e limited due to safety concerns. This suggestion was con-
rmed by our findings.
ntensity of care. We cannot differentiate whether intensi-
ed patient management provided to high-risk patients of the
M group or NT-proBNP–guided management contributed
ore to improving outcomes, as this was not the aim of our
tudy. However, recently, a large multicenter trial (the
OACH [Coordinating Study Evaluating Outcomes of Ad-
ising and Counseling in Heart Failure]) demonstrated that
ncreasing the intensity of care from moderate to intensive
isease management has no beneficial effect (25). As also
hown in other studies, the intensive care strategy even tended
o increase the number of HF rehospitalizations. The reason
or this may be the low-threshold access to care providers,
esulting in relatively easy hospital admission in case of clinical
eterioration. In contrast, our approach in the BM group led to
decrease in the number of rehospitalizations. The assessment
f NT-proBNP allowed for the monitoring of short-term
hanges in cardiac wall stress and, thereby, the anticipation of
ardiac decompensation, which facilitated medical adjustment
n advance. Interestingly, the increase in the number of
cheduled contacts for the BM group did not significantly
ncrease overall contacts with HF specialists, as unscheduled
ontacts due to clinical deterioration decreased in trend when
ompared with MC alone.
tudy limitations. Of 441 eligible patients, 163 (37%)
efused to participate in the study. This phenomenon has
een described previously (26) and can be attributed to
atients’ inability to attend scheduled ambulatory visits due
o reduced mobility (comorbidities, high age, reduced social
ontacts), the unwanted intrusion into patients’ privacy
uring home visits, and negative psychology associated with
eing a test subject. As a result, study subjects may have
een more motivated than those refusing to participate may
ave been, a fact that might have positively influenced the
utcome in the intervention groups but also in the UC
roup. However, as a similar selection bias can be expected
n real-world multidisciplinary programs, we can assume
hat the results of this study also apply to daily clinical
ractice. Another limitation represents the fact that both
he patients and providers knew they were in an intervention
roup (BM and MC). This awareness might have resulted in
competitive stimulus with optimal dedication of the providers
nd compliance of the patients. In reality, effects might be
ower. Moreover, the study group consists almost entirely of
atients with systolic dysfunction. Therefore, our study does
ot provide information regarding the effect of BM in the large
ubgroup of CHF patients with preserved ejection fraction.
ost-effectiveness. Cost-effectiveness is an important fac-
or in the context of HF management programs. Although
he number of programs increased during the last few years,
ealth care insurance covers the costs in only a small
roportion of programs. Many HF programs are financed
artly or completely by the pharmaceutical industry, a fact
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February 16, 2010:645–53 NT-ProBNP–Guided, Intensive Patient Managementhat imposes a threat for their continuity (27). Therefore,
he question faced is how to focus limited resources on the
atients who are in need of such an intervention. Our study
oes not only demonstrate that MC improves outcome but
lso shows that focusing intensified care to high-risk pa-
ients improves outcome without further increasing the
onsumption of resources. Thereby, this concept might
mprove the cost-effectiveness ratio of HF programs.
onclusions
ur study proves the concept of applying intensified treatment
o patients at high risk for cardiac decompensation selected via
T-proBNP levels and of adjusting medical treatment in
dvance according to short-term changes in NT-proBNP
evels. However, deployment of this concept (BM) using
mbulatory HF specialists and home nurses may not be feasible
n all health care systems, and further adaptation of this
pproach will be necessary in different settings. As primary care
s not very effective in the management of these patients, BM
ay only be successful in combination with other disease
anagement programs. Most European and North American
ountries have established HF units, which could use BM to
elect high-risk patients for intensified care and discharge them
o less intensive care following stabilization. It could be
xpected that BM combined with a disease management
rogram, such as an HF unit, improves the outcome of the HF
opulation without the use of increasing personal and financial
esources. It will be worthwhile to study such possibilities,
specially in light of the current financial strain on most health
are systems.
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